Johnson & Johnson Reports Strong Earnings Amid Geopolitical Challenges
Johnson & Johnson reported third-quarter earnings that exceeded Wall Street expectations, driven by strong performance of its immune disease treatment Tremfya. The company posted revenue of $25.4 billion and adjusted earnings per share (EPS) of $2.59, both above analyst estimates. However, geopolitical issues such as the Middle East conflict negatively impacted sales in its medical-device division. The pharmaceutical segment saw a 7.7% increase to $16.76 billion, while the medical technology division grew only slightly at 2.5%. CFO Joe Wolk noted that international markets are being affected by austerity measures and reallocation of budgets toward defense due to ongoing conflicts. Tremfya sales surged 68%, outpacing expectations, but Stelara revenue dropped sharply amid generic competition. Johnson & Johnson raised its full-year sales forecast slightly to $101.2 billion at the midpoint and increased its adjusted earnings guidance with a new EPS of $11.10 per share.
Tickers: $JNJ
Topics: Geopolitical Impact Medical Devices Pharmaceuticals Sales Performance